Quest For 10-Baggers in BioHealth in 2010 (JAZZ, TRGT, VNDA, DNDN, HGSI, CGEN, BNVI, QCOR, ACHN, PSDV, ATHX, SNSS, AVNR, BIOD, ALXA, CTIC)

If one thing was noticed in biotech stocks, or BioHealth stocks as we often say, it was that investors, traders, and speculators all piled into the chase for the next ten-bagger late in the year.  When you have as many biotech and BioHealth stocks that ran over 1,000% in 2009 that is only to be expected…. hence the 10-bagger comments.  We had many biotech and biohealth shares rally from their lows significantly this year, with companies such as Jazz Pharmaceuticals, Inc. (NASDAQ: JAZZ), Targacept, Inc. (NASDAQ: TRGT), Vanda Pharmaceuticals, Inc. (NASDAQ: VNDA), Dendreon Corp. (NASDAQ: DNDN), and Human Genome Sciences, Inc. (NASDAQ: HGSI) all being in or having been in the 10-bagger club this year.

But late in 2009 we started seeing an onslaught of low-priced stocks with small cap or micro-cap values running rapidly higher on news.  In some cases these faded, and in some not.  We saw the traders run up shares of Compugen Ltd. (NASDAQ: CGEN), Bionovo, Inc. (NASDAQ: BNVI), Questcor Pharmaceuticals, Inc. (NASDAQ: QCOR), Achillion Pharmaceuticals, Inc. (NASDAQ: ACHN), pSivida Corp. (NASDAQ: PSDV), Athersys, Inc. (NASDAQ: ATHX), Sunesis Pharmaceuticals, Inc. (NASDAQ: SNSS), and AVANIR Pharmaceuticals, Inc. (NASDAQ: AVNR) on news late in 2009.  Also covered as potentials for this are Biodel Inc. (NASDAQ: BIOD), Alexza Pharmaceuticals, Inc. (NASDAQ: ALXA), and Cell Therapeutics, Inc. (NASDAQ: CTIC).

We have reviewed each of these and given a synopsis for each to see if these could be the 10-baggers for 2010.
Read more

A New Potential Blockbuster in Major Depressive Disorder? (TRGT, AZN)

July 15, 2009 · Filed Under Depression, targacept · Comments Off 

Targacept, Inc. (NASDAQ: TRGT) is not exactly a household name.  But if things continue in the add-on treatment trial news for major depressive disorder then this may be more of a household name.  The company has announced that its TC-5214 has achieved all primary and secondary endpoints in its Phase 2b Trial.  This is an augmentation treatment (add-on treatment) study aimed for major depressive disorder.

The TC-5214 Phase IIb study is a a double blind, placebo controlled, flexible dose trial as an add-on treatment.  This disorder is at least a part of one of the top arenas for drug spending.  It met all endpoints in subjects who did not respond adequately to first-line treatment with citalopram alone.
Read more

BlogFile: Targacept, Inc. (TRGT)

May 13, 2007 · Filed Under blogfile, targacept · Comment 

BioHealth Investor.com

COMPANY BlogFILE
updated: May 13, 2007

TARGACEPT, Inc.

200 East First Street, Suite 300
Winston-Salem, NC 27101-4165
USA
Phone: (336) 480-2100
Fax: (336) 480-2107
www.targacept.com

Investor/Public Relations
Alan Musso
Vice President and Chief Financial Officer
(336) 480-2186
(336) 480-2103
alan.musso@targacept.com

COMPANY DESCRIPTION

Targacept, Inc. is a biopharmaceutical company engaged in the design, discovery and development of NNR Therapeutics™, a new class of drugs for the treatment of multiple diseases and disorders of the central nervous system. Our NNR Therapeutics selectively target neuronal nicotinic receptors, or NNRs.NNrs are found on nerve cells throughout the nervous system and serve as key regulators of nervous system activity.

BUSINESS INFORMATION

Public company
Ticker: TRGT
Market: NASDAQ
Industry: Biotechnology

LATEST BLOG COMMENTARY

Tiny Targacept Experiences Unusual Volume Surge
SeekingAlpha
April 18, 2007

Targacept: Late Day Volume Surge Deserves Attention
BioHealth Investor
April 17, 2007

Wednesday Pre-market Notes By Stock Ticker
SeekingAlpha
April 12, 2007

Barron’s Alzheimer’s Article Only Scratches the Surface
24/7 Wall St.
March 31, 2007

Friday’s Top Biotech and Medical Stocks
BioHealth Investor
November 04, 2007

Thursday’s Top Biotech and Medical Stocks
BioHealth Investor
November 02, 2006

Source: BioHealth Investor.com

___________________

    Subscribe to BioHealth Investor BioHealth Investor RSS Feed